Activist investor blasts Alexion's $1.4B Portola buy in scathing open letter

12th May 2020 Uncategorised 0

Nearly four years removed from a disastrous sales fraud probe and an overhaul of its senior leadership, Alexion has launched a dealmaking campaign to bolster its rare disease pipeline. But one activist investor thinks Alexion’s strategy is ill-conceived—and the old foe is airing its grievances in public. 

More: Activist investor blasts Alexion's .4B Portola buy in scathing open letter
Source: fierce